Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study.

ABSTRACT:

Background

Patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) usually present with metastatic disease and have a poor prognosis. No standard therapies have been established beyond the first-line platinum-based chemotherapy. This study aims to evaluate the efficacy and safety of nab-paclitaxel plus bevacizumab in patients with previously treated advanced EP-NEC.

Methods

This multicenter, single-arm, phase 2 trial was conducted from January 2021 to March 2024 to evaluate the efficacy and safety of nab-paclitaxel plus bevacizumab in patients with advanced EP-NEC who progressed after prior standard-of-care treatments. Patients were assigned to receive nab-paclitaxel of 150 mg/m² plus bevacizumab of 5 mg/kg intravenously every 2 weeks in a cycle un

SUBMITTER: Zhang P 

PROVIDER: S-EPMC12595278 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature